Venous Thrombosis
132
3
6
90
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
34 trials with published results (26%)
Research Maturity
90 completed trials (68% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.8%
9 terminated out of 132 trials
90.9%
+4.4% vs benchmark
30%
40 trials in Phase 3/4
38%
34 of 90 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 90 completed trials
Clinical Trials (132)
Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
Intimate Partner Violence as a Risk Factor for Venous Thromboembolism in Women
Free DNA and Nucleosome Concentrations in Pathological Pregnancies
Epidemiology of Venous Thrombosis and Pulmonary Embolism
The Correlation Between Circulatory Tumor Cells and Venous Thrombosis
Diagnostic Validity of [18F]GP1 PET for Diagnosing Acute Deep Vein Thrombosis
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
JETi Lower Extremity Venous Thrombosis
Evaluation of the Duration of Therapy for Thrombosis in Children
A Study of MK-2060 in Healthy Participants (MK-2060-016)
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
PeriOperative ISchemic Evaluation-3 Trial
Prospective Assessment of the Deep Vein Thrombosis (DVT) in Hospitalized Obstetrics Patients
Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture
Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study